Literature DB >> 18301128

Proposal for the development of a standardized protocol for assessing the economic costs of HIV prevention interventions.

Steven D Pinkerton1, Cynthia R Pearson, Susan R Eachus, Karina M Berg, Richard M Grimes.   

Abstract

Maximizing our economic investment in HIV prevention requires balancing the costs of candidate interventions against their effects and selecting the most cost-effective interventions for implementation. However, many HIV prevention intervention trials do not collect cost information, and those that do use a variety of cost data collection methods and analysis techniques. Standardized cost data collection procedures, instrumentation, and analysis techniques are needed to facilitate the task of assessing intervention costs and to ensure comparability across intervention trials. This article describes the basic elements of a standardized cost data collection and analysis protocol and outlines a computer-based approach to implementing this protocol. Ultimately, the development of such a protocol would require contributions and "buy-in" from a diverse range of stakeholders, including HIV prevention researchers, cost-effectiveness analysts, community collaborators, public health decision makers, and funding agencies.

Mesh:

Year:  2008        PMID: 18301128      PMCID: PMC2536744          DOI: 10.1097/QAI.0b013e3181605a98

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  3 in total

Review 1.  Assessing the efficiency of HIV prevention around the world: methods of the PANCEA project.

Authors:  Elliot Marseille; Lalit Dandona; Joseph Saba; Coline McConnel; Brandi Rollins; Paul Gaist; Mattias Lundberg; Mead Over; Stefano Bertozzi; James G Kahn
Journal:  Health Serv Res       Date:  2004-12       Impact factor: 3.402

2.  A structured instrument for estimating the economic cost of drug abuse treatment. The Drug Abuse Treatment Cost Analysis Program (DATCAP).

Authors:  M T French; L J Dunlap; G A Zarkin; K A McGeary; A T McLellan
Journal:  J Subst Abuse Treat       Date:  1997 Sep-Oct

Review 3.  Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine.

Authors:  J E Siegel; M C Weinstein; L B Russell; M R Gold
Journal:  JAMA       Date:  1996 Oct 23-30       Impact factor: 56.272

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.